Pfizer Inc (PFE) 30.49 $PFE
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - 32 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Puma Biotechnology Inc's Overnight Triple is Just the Beginning
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 7:03PM CDT
Look at that cat go. Puma Biotechnology more than tripled in afterhours after announcing that its phase 3 trial testing neratinib in breast cancer patients was successful. The trial enrolled patients with early breast tumors having a mutation...
Johnson & Johnson Announces $5B Share Buyback - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 5:25PM CDT
Johnson & Johnson (JNJ) announced its plan to buy back up to $5 billion of its common stock.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 10:01AM CDT
Shares of Shire (SHPG) gained 1.43% following the news of an acquisition agreement with AbbVie (ABBV) as well as better-than-expected second quarter results. Thereafter, shares lost 1.6%.
2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.24%
Comtex SmarTrend(R) - Mon Jul 21, 3:44PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.30 to a high of $30.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.34 on volume of 22.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.24%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jul 21, 3:43PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $30.30 to a high of $30.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.34 on volume of 22.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pfizer's Stock Falls Ill as the Dow Tumbles
Dan Carroll, The Motley Fool - Motley Fool - Mon Jul 21, 1:35PM CDT
Stocks got off to a bad start to the week, and while the Dow Jones Industrial Average has made its way back from tough losses earlier today, the index was still 40 points in the red as of 2:30 p.m. EDT. A clear majority of its member stocks were...
Pfizer (PFE) Approaches New Downside Target of $30.20
Comtex SmarTrend(R) - Mon Jul 21, 10:42AM CDT
Shares of Pfizer (NYSE FE) opened today below their pivot of $30.61 and have already reached the first level of support at $30.46. Investors may be interested in a cross of the next downside pivot targets of $30.20 and $29.79.
Early Glance: Pharmaceuticals companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Global Meningococcal Vaccines Pipeline Market 2013-2019, Namely, Bexsero, MnB rLP2806 and NmVac-4DT
M2 - Mon Jul 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7js4c/meningococcal) has announced the addition of the "Global Meningococcal Vaccines Pipeline Market 2013-2019, Namely, Bexsero, MnB rLP2806 and NmVac-4DT" report to their offering. The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate and combination vaccines. The vaccine types are further segmented into different brands. The report also highlights and analyzes various brands under pipeline segment, namely, Bexsero, MnB rLP2806 and NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2011 to 2019. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2013 to 2019, while market size estimations have been made considering 2011 and 2012 as the base years. The report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd. Report Scope Meningococcal Vaccines Market, by Type Polysaccharide Vaccines, by Brand - Menomune - Mencevax - NmVac4 - Others - - Quadri Meningo - - Bi Meningo Conjugate Vaccines, by Brand - Menactra - Menveo - NeisVac-C - Nimenrix - Meningitec - Menjugate - MenAfriVac Combination Vaccines, by Brand - MenHibrix - Menitorix Pipeline Vaccines, by Brand - Bexsero - MnB rLP2806 - NmVac4-DT Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Meningococcal Vaccines Market Overview Chapter 4 Global Meningococcal Vaccines Market, by Type Chapter 5 Global Meningococcal Vaccines Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Baxter International, Inc. - Biomed Pvt. Ltd. - GlaxoSmithKline plc - JN-International Medical Corporation - Novartis International AG - Nuron Biotech, Inc. - Pfizer, Inc. - Sanofi SA - Serum Institute of India Ltd. For more information visit http://www.researchandmarkets.com/research/x7...ingococcal
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 3:45PM CDT
Bristol-Myers (BMY) and Pfizer (PFE) Began enrolling patients in a study on Eliquis.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - 32 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Puma Biotechnology Inc's Overnight Triple is Just the Beginning
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 7:03PM CDT
Look at that cat go. Puma Biotechnology more than tripled in afterhours after announcing that its phase 3 trial testing neratinib in breast cancer patients was successful. The trial enrolled patients with early breast tumors having a mutation...
Johnson & Johnson Announces $5B Share Buyback - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 5:25PM CDT
Johnson & Johnson (JNJ) announced its plan to buy back up to $5 billion of its common stock.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 10:01AM CDT
Shares of Shire (SHPG) gained 1.43% following the news of an acquisition agreement with AbbVie (ABBV) as well as better-than-expected second quarter results. Thereafter, shares lost 1.6%.
2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.24%
Comtex SmarTrend(R) - Mon Jul 21, 3:44PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.30 to a high of $30.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.34 on volume of 22.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. After Yesterday's Decline of 1.24%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jul 21, 3:43PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.30 to a high of $30.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.34 on volume of 22.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Pfizer's Stock Falls Ill as the Dow Tumbles
Dan Carroll, The Motley Fool - Motley Fool - Mon Jul 21, 1:35PM CDT
Stocks got off to a bad start to the week, and while the Dow Jones Industrial Average has made its way back from tough losses earlier today, the index was still 40 points in the red as of 2:30 p.m. EDT. A clear majority of its member stocks were...
Pfizer (PFE) Approaches New Downside Target of $30.20
Comtex SmarTrend(R) - Mon Jul 21, 10:42AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $30.61 and have already reached the first level of support at $30.46. Investors may be interested in a cross of the next downside pivot targets of $30.20 and $29.79. Early Glance: Pharmaceuticals companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Global Meningococcal Vaccines Pipeline Market 2013-2019, Namely, Bexsero, MnB rLP2806 and NmVac-4DT
M2 - Mon Jul 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7js4c/meningococcal) has announced the addition of the "Global Meningococcal Vaccines Pipeline Market 2013-2019, Namely, Bexsero, MnB rLP2806 and NmVac-4DT" report to their offering. The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate and combination vaccines. The vaccine types are further segmented into different brands. The report also highlights and analyzes various brands under pipeline segment, namely, Bexsero, MnB rLP2806 and NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2011 to 2019. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2013 to 2019, while market size estimations have been made considering 2011 and 2012 as the base years. The report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd. Report Scope Meningococcal Vaccines Market, by Type Polysaccharide Vaccines, by Brand - Menomune - Mencevax - NmVac4 - Others - - Quadri Meningo - - Bi Meningo Conjugate Vaccines, by Brand - Menactra - Menveo - NeisVac-C - Nimenrix - Meningitec - Menjugate - MenAfriVac Combination Vaccines, by Brand - MenHibrix - Menitorix Pipeline Vaccines, by Brand - Bexsero - MnB rLP2806 - NmVac4-DT Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Meningococcal Vaccines Market Overview Chapter 4 Global Meningococcal Vaccines Market, by Type Chapter 5 Global Meningococcal Vaccines Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Baxter International, Inc. - Biomed Pvt. Ltd. - GlaxoSmithKline plc - JN-International Medical Corporation - Novartis International AG - Nuron Biotech, Inc. - Pfizer, Inc. - Sanofi SA - Serum Institute of India Ltd. For more information visit http://www.researchandmarkets.com/research/x7...ingococcal
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 3:45PM CDT
Bristol-Myers (BMY) and Pfizer (PFE) Began enrolling patients in a study on Eliquis.
